<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110926">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01877265</url>
  </required_header>
  <id_info>
    <org_study_id>14594</org_study_id>
    <secondary_id>I2R-MC-BIDH</secondary_id>
    <nct_id>NCT01877265</nct_id>
  </id_info>
  <brief_title>A Study of LY2605541 in Healthy Participants</brief_title>
  <official_title>Assessment of the Impact of Monomethoxy Polyethylene Glycols on the Pharmacokinetics and Glucodynamics of Single Doses of LY2605541 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at the amount of LY2605541 in the body after it is injected under the skin.
      The study has 3 periods, each lasting 10 days. Each participant will receive one injection
      in each period. At least 14 days will pass between each injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Time Curve from Zero to Infinity (AUC[0-âˆž]) of LY2605541</measure>
    <time_frame>Predose up to 216 hours post dose in each period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541</measure>
    <time_frame>Predose up to 216 hours post dose in each period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics: Maximum Glucose Infusion Rate (Rmax)</measure>
    <time_frame>Predose up to 216 hours post dose in each period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics: Total Amount of Glucose Infused (Gtot)</measure>
    <time_frame>Predose up to 216 hours post dose in each period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY2605541 - Source 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each healthy participant will receive a single subcutaneous (SQ) injection of 0.5 units per kilogram (U/kg) of LY2605541 on Day 1 of three treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541 - Source 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each healthy participant will receive single SQ injection of 0.5 U/kg of LY2605541 on Day 1 of one of three treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541 - Source 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each healthy participant will receive single SQ injection of 0.5 U/kg of LY2605541 on Day 1 of one of three treatment periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2605541</intervention_name>
    <arm_group_label>LY2605541 - Source 1</arm_group_label>
    <arm_group_label>LY2605541 - Source 2</arm_group_label>
    <arm_group_label>LY2605541 - Source 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination

          -  A body mass index of 18.5 to 30 kilograms per meter square (kg/m^2)

        Exclusion Criteria:

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Are women with a positive pregnancy test or are women who are lactating

          -  Intend to use over-the-counter medication within 7 days prior to dosing or
             prescription medication within 14 days prior to dosing (apart from contraceptive
             medication, vitamin/mineral supplements, occasional acetaminophen, and/or hormone
             replacement therapy)

          -  Have donated blood of more than 500 milliliters (mL) within the last month

          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14
             units per week (females)

          -  Are excessive consumers of xanthines (more than 10 cups of tea, coffee, cola or hot
             chocolate per day)

          -  Have a fasting blood glucose (BG) &gt;110 milligrams per deciliter (mg/dL) (6.1
             millimoles per liter [mmol/L])

          -  Currently smoke more than 10 cigarettes per day, or are unwilling to refrain from
             smoking for 72 hours prior to each dosing occasion and during confinement
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 30, 2013</lastchanged_date>
  <firstreceived_date>June 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
